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The Legionella effector WipB is a 
translocated Ser/Thr phosphatase 
that targets the host lysosomal 
nutrient sensing machinery
Marie S. Prevost, Nikos Pinotsis, Maud Dumoux, Richard D. Hayward & Gabriel Waksman
Legionella pneumophila infects human alveolar macrophages and is responsible for Legionnaire’s 
disease, a severe form of pneumonia. L. pneumophila encodes more than 300 putative effectors, which 
are translocated into the host cell via the Dot/Icm type IV secretion system. These effectors highjack 
the host’s cellular processes to allow bacterial intracellular growth and replication. Here we adopted 
a multidisciplinary approach to investigate WipB, a Dot/Icm effector of unknown function. The crystal 
structure of the N-terminal domain at 1.7 Å resolution comprising residues 25 to 344 revealed that 
WipB harbours a Ser/Thr phosphatase domain related to the eukaryotic phospho-protein phosphatase 
(PPP) family. The C-terminal domain (residues 365–524) is sufficient to pilot the effector to acidified 
LAMP1-positive lysosomal compartments, where WipB interacts with the v-ATPase and the associated 
LAMTOR1 phosphoprotein, key components of the lysosomal nutrient sensing (LYNUS) apparatus that 
controls the mammalian target of rapamycin (mTORC1) kinase complex at the lysosomal surface. We 
propose that WipB is a lysosome-targeted phosphatase that modulates cellular nutrient sensing and the 
control of energy metabolism during Legionella infection.
Legionella pneumophila is a facultative intracellular pathogen responsible for a severe form of pneumonia termed 
Legionnaire’s Disease1. Infection occurs via the inhalation of aerosols, followed by phagocytosis of the bacterium 
by alveolar macrophages. Within the macrophage, the bacterium avoids the endosomal pathway by modifying the 
early entry vesicle into a specialised replicative compartment termed the “Legionella-Containing Vacuole” (LCV), 
which progressively acquires endoplasmic reticulum-derived membranes, studded with ribosomes2.
During infection, L. pneumophila utilizes a type IV secretion (T4S) system termed the Dot/Icm secretion sys-
tem to translocate effector proteins into the host cell3–7. Over 300 potential effectors are translocated by the Dot/
Icm system. These effectors are encoded on the L. pneumophila chromosome and their genes comprise approxi-
mately 10% of the bacterium’s genome8, 9. About 20% of the effectors have been linked to a cellular pathway, and 
of these only half have an ascribed eukaryotic target or biochemical function2. Although the deletion of the T4S 
secretion system itself impairs intracellular growth, bacterial mutants lacking individual effectors only exhibit 
mild defects in intracellular replication. Indeed, several studies have demonstrated that multiple, redundant effec-
tors target the same cellular process2. These factors complicate the dissection of Legionella effector activities.
IcmW-Interacting Protein B (WipB) is a 60 kDa Legionella effector of unknown function originally identified 
amongst a cohort of proteins that interact with the Dot/Icm T4S chaperone complex IcmS/IcmW10. Legionella 
deletion mutants lacking wipB do not exhibit a replicative defect in macrophages, unless this is combined with 
a second mutation in lidA, a gene encoding another T4S effector capable of binding Rab GTPases. L. pneumo-
phila wipB−lidA− double mutants exhibit attenuated intracellular replication in macrophages and increased host 
cell death, although the significance of this remains unclear2, 11. Given this characteristic lack of attenuation in 
the single gene deletion mutant, a hallmark of functional redundancy, we adopted an alternative structural and 
biochemical approach to explore the properties and target/s of WipB. Our data reveal that WipB is a modular 
effector, with an N-terminal Ser/Thr phosphatase domain related to the eukaryotic phospho-protein phosphatase 
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(PPP) family, and a C-terminal domain sufficient to pilot WipB to the acidified LAMP1-positive lysosomal com-
partments in eukaryotic cells, where WipB interacts with the v-ATPase and the associated LAMTOR1 phosphop-
rotein, key components of the lysosomal nutrient sensing (LYNUS) apparatus.
Results and Discussion
The structure of the WipB N-terminal domain reveals a phosphatase domain. WipB was purified 
following over-expression in E. coli as described in Materials and Methods. However, we observed rapid break-
down of the protein into shorter fragments (Fig. 1a), the shortest of which was identified by mass spectrometry to 
contain the first 364 residues of the protein. A construct encoding this apparently stable fragment was generated 
and the protein expressed and purified (Fig. 1a). This fragment, WipB1-364, was stable but did not crystallise. 
Thus, the construct was further modified to exclude the regions of the N- or C-terminal sequence predicted to 
have no secondary structures (regions 1–24 and 345–364). The resulting fragment, WipB25-344, also yielded a 
stable protein, which in contrast to WipB1-364 crystallised readily. The crystals diffracted to a resolution of 1.7 Å 
(Table 1). The structure was solved using the Molecular Replacement method, with the recently solved structure 
of WipA (a protein with 34% identity at amino acid sequence level (Fig. S1)) serving as a search model12. Attempts 
to similarly produce the C-terminal domain of WipB failed, as this region of the protein appears to be unstable 
when expressed in bacteria. Thus, WipB appears to contain two domains, a structured N-terminal domain and a 
possibly less stable C-terminal domain.
WipB25-344 crystallizes as a dimer in the asymmetric unit. While the two chains superpose very well 
(root-mean-square deviation (RMSD) in Cα atoms of 0.5 Å), chain A exhibits overall lower B-factors (Fig. S2a). In 
chain A, density for residues 332–344 is missing while the same region is resolved in chain B (Fig. S2b), This region 
in chain B interacts with chain A, probably an artefact of crystal packing as WipB25-344 is monomeric in solution.
Figure 1. Domain structure of WipB and WipB25-344 structure (a) SDS-PAGE analysis of WipB and WipB 
fragments. Lane 1: full-length WipB. Lane 2: WipB1-364. Lane 3: WipB25-344. (b) Topology diagram of WipB25-344.  
β-strands and α-helices are shown as arrows and cylinders, respectively. The central β-sandwich is shown in 
blue and yellow. The flanking α-helices on the side of the blue or yellow β-sheets are shown in cyan and red, 
respectively. The three helices at the top are shown in green. (c) Three-dimensional diagram of WipB25-344. The 
structure is shown in cartoon representation with secondary structures color-coded as in panel B.
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WipB25-344 forms a compact structure consisting of a central β-sandwich and 11 α-helices, 4 α-helices on 
each side of the β-sandwich (in cyan (α1-4) and red (α8-11), respectively, in Fig. 1b,c) with three more α-helices 
(α5-7) capping the structure (in green in Fig. 1b,c). The structure can be further subdivided in an N-terminal 
lobe consisting of α1-4 and β1-3 (cyan and blue in Fig. 1b,c) on the one hand and a C-terminal lobe consisting 
of α8-11 and β4-6 (in red and yellow in Fig. 1b,c) on the other hand. The structure of WipB25-344 is very similar to 
that of WipA24-435 determined previously (the structures align with a root-mean-square deviation in Cα atoms 
of 1.9 Å over 279 WipB residues; Fig. S2c). However, WipA differs from WipB in including a very large α-helical 
hairpin (Fig. S2c).
A search for similar structures using the DALI server13 highlighted several hydrolases among the highly 
scored homologous structures, including the catalytic domain of a number of serine/threonine (Ser/Thr) protein 
phosphatases including PP1, PP2A, PP2B, and PP5, important members of the larger phospho-protein phos-
phatase (PPP) family of proteins14 Structural superposition of WipB25-344 with these eukaryotic phosphatases 
(see Fig. S1 for sequence alignment with a number of PPPs, and Figs S2d and 2a for structural superposition with 
PP2B) reveals a common structural core aligning with an RMSD in Cα atoms of 2 Å. This core consists of the 
central β-sandwich together with the flanking helices α1, α4, and α6 on one side and α8 and α11 on the other. 
Importantly, these regions harbour signature motifs conserved in PPPs, notably Ser/Thr phosphatases (Fig. 2a). 
In the PPP family, the DxH, GDxxDR, and NHE signature motifs are strictly conserved and comprise most of 
the residues that form the catalytic site14 WipB exhibits similar motifs, namely GDLHA, GDELVDR, and NHG 
(Fig. 2a and S1), and these motifs cluster in one particular region of WipB25-244, on the loops connecting β1 and 
α1 (GDLHA), β2 and α4 (GDELVDR), and β3 and α5 (SNG). In this region, the side chains of Asp 32 and His 34 
(in GDLHA), Asp118 and Asp122 (in GDELVDR) and of His 151 (in NHG) form a site which in PP2B and other 
Ser/Thr phosphatase has been shown to be the catalytic site of these enzymes (Fig. 2b). Two additional residues 
are located in this cluster, His 231 and Asp 331, both conserved and known to be important for activity in PP2B 
and other PPPs (Fig. 2b).
WipB is a Ser/Thr phosphatase. The structural homology of WipB25-244 with phosphatases of the PPP 
family suggests that WipB might contain a Ser/Thr phosphatase activity. To test this hypothesis, we investigated 
WipB 25-344
Data Collection
Beamline PX13 (EMBL-PETRA III)
Wavelength (Å) 0.99999
Resolution Range (Å) 48.83–1.70 (1.74–1.70)
Space group P 21
Cell parameters a, b, c, β (Å, grad) 49.40, 79.10, 49.70, 98.70
Total reflections 240,903 (16,864)
Unique reflections 66,193 (4,732)
Multiplicity 3.6 (3.6)
Completeness (%) 99.3 (97.1)
Mean I/Sigma(I) 8.73 (1.21)
Wilson B-factor (Å2) 24.67
Rsym (%) 11.6 (115.1)
CC1/2 0.996 (0.480)
Refinement
Rwork/Rfree (%) 18.7/21.7
CCwork/CCfree 0.955/0.938
Protein atoms 5089
Solvent molecules 484
B-factor (Å2) 22.10
Protein 60.91
Solvent 56.39
Ramachandran Plot
Favored (%) 96.15
Allowed (%) 3.69
Outliers (%) 0.16
Clash score 5.34
Rmsd
Bonds (Å) 0.007
Angles (grad) 0.880
PDB code 5NNY
Table 1. Data collection and refinement statistics. Information for the highest resolution shell is given in 
parentheses.
www.nature.com/scientificreports/
4Scientific RepoRTs | 7: 9450  | DOI:10.1038/s41598-017-10249-6
the ability of the WipB N-terminal domain (residues 1-364) to catalyse dephosphorylation reactions in vitro using 
a model phosphothreonine peptide with sequence RRA(pT)VA, a peptide derived from the rat liver pyruvate 
kinase and routinely used to monitor Ser/Thr phosphatase activities15. As shown in Fig. 2c, WipB1-364 clearly 
exhibits phosphatase activity. Biochemical quantification of the initial rates at 21 °C revealed a Km of 0.5 ± 0.3 mM 
and a Vmax of 0.042 ± 0.02 mM.s−1 for the dephosphorylation reaction using 30 nM of WipB1-364.
Since WipB and WipA are structurally similar and WipA exhibits tyrosine protein phosphatase activity, we 
next tested the activity of WipB against a phosphotyrosine-containing peptide (Fig. 2c). The model peptide 
END(pY)INASL (a peptide derived from the T cell phosphatase sequence16 and generally used to assay tyrosine 
phosphatase activities) was used as substrate in the presence of 0, 10, 30 and 90 nM of WipB1-364 and the released 
free phosphate concentration was measured after incubation at 37 °C for 2 minutes (Fig. 2c). The same experi-
ment was carried out using the RRA(pT)VA peptide for comparison. We observed that WipB1-364 is able to release 
phosphate from the phosphothreonine, not the phosphotyrosine, peptide. Another phosphotyrosine-containing 
peptide routinely used to monitor tyrosine dephosphorylation was also used, with sequence DADE(pY)LIPQQG 
derived from the EGFR protein17, and the lack of activity against phosphotyrosine-containing sequences was 
confirmed (data not shown).
In order to assess whether the active site identified from comparison with the structure of PP2B is responsible 
for the measured phosphatase activity, we expressed and purified three derivatives of WipB1-364 each containing 
an individual point mutation within the putative active site: Asp118 to Ala (WipB1-364;D118A; in GDLHA motif) and 
Arg123 to Ala (WipB1-364;R123A; in the GDELVDR motif) and His151 to Ala (WipB1-364;H151A; in the NHG motif). 
Figure 2. WipB is related to the PPP phosphatases (a) Structure-based alignment of the core part of the 
structure conserved between the human phosphatase PP2B (grey, pdb code 5C1V) and WipB (purple). Both 
structures are in cartoon representation. The three phosphatase motifs, GDLHA, GDELVDR, and NHG, 
are mapped onto the structure and color-coded in orange, green and blue, respectively. Orientation is the 
same than in Fig. 1c. (b) Active site of WipB and PP2B. The two proteins are shown as in panel A in the same 
orientation. Residues of the active site of PP2B conserved in WipB are shown in ball-and-stick representation, 
with oxygen and nitrogen atoms color-coded in blue and red, respectively. For residues in the three phosphatase 
motifs GDLHA, GDELVDR, and NHG, carbon atoms are color-coded in orange, green or blue, respectively. 
(c) Activity assay of WipB1-364. Left panel: release of free phosphate over time from the RRA(pT)VA peptide 
incubated at 37 °C with 30 nM of WipB1-364. Right panel: phosphate release measurements using increasing 
concentrations of WipB1-364 wild-type or mutant incubated for 2 minutes at 37 °C with either the RRA(pT)VA 
(solid line) or the END(pY)INASL (dashed line) peptide. Results with the wild-type protein establish that WipB 
is a Ser/Thr protein phosphatase while results obtained with the mutants ascertain the catalytic role of residues 
conserved in the structural alignment with PPPs.
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The three mutants exhibited a loss in phosphatase activity confirming that the catalytic domain predicted from 
our structure is indeed functional (Fig. 2c).
To understand the differences between WipB and WipA specificity, we compared the structure of their cata-
lytic sites (Fig. S2e). Both are essentially similar. However, four residues differ in position: Arg185 (123 in WipA), 
Asp30 (31 in WipA), Asp396 (331 in WipA) and Asp310 (369 in WipA). In WipA, the first three are involved in 
catalysis while Arg369 of WipA was hypothesized to be involved in pTyr recognition12. In WipB, Arg310 (equiv-
alent of Arg369 in WipA), is conformationally restrained away from the active site and therefore cannot assume a 
role in substrate recognition. We hypothesize that this is the reason why WipB is inactive against pTyr-containing 
peptides.
Altogether, these data demonstrate that WipB harbours a functional N-terminal phosphatase domain that can 
hydrolyse Ser/Thr phosphorylated peptides in vitro and is catalytically independent from the C-terminal domain.
WipB locates to the lysosomal compartment and its C-terminal domain determines its cellular 
localisation. Having established that WipB is a Ser/Thr protein phosphatase, we next investigated the locali-
sation of WipB when expressed in cultured mammalian cells.
Cultured HeLa cells were transiently transfected with plasmids encoding GFP fusions of WipB, either at 
the C-terminus (WipB-GFP) or the N-terminus (GFP-WipB). After 24 h, immunoblotting of transfected cell 
lysates using an anti-GFP antibody revealed the presence of a single species at the expected molecular weight of 
WipB-GFP and GFP-WipB (Fig. S3a), verifying that in contrast to expression in E. coli, the fusion proteins were 
not truncated or degraded, irrespective of the location of the GFP.
When transfected HeLa cells were examined using confocal microscopy, GFP-WipB and WipB-GFP predom-
inantly formed puncta in the cytoplasm, with a minor fraction also evident at the plasma membrane (Fig. 3a for 
GFP-WipB and Fig. S3b for WipB-GFP). Equivalent localisation was observed when cultured retinal pigment 
epithelial (RPE-1) cells were transiently transfected with GFP-WipB (Fig. S3c).
Figure 3. WipB is targeted to lysosomes by its C-terminal domain where it interacts with components of the 
lysosomal nutrient sensing system (a) HeLa cells expressing GFP-fusion proteins of WipB, WipBD118A, WipB1-364 
and WipB365-524. Scale bar, 10 µm. (b) HeLa cells expressing GFP-WipB (green) stained using an anti-LAMP-1 
antibody (Magenta) after permeabilisation and fixation. Scale bar, 10 µm. (c) HeLa cells expressing GFP-WipB 
(green) were incubated with Lysotracker (red) for 15 min before fixation. Scale bar, 10 µm. (d) SDS-PAGE 
of fractions following co-immunoprecipitation of GFP, GFP-WipB or the indicated GFP-WipB derivatives 
from HeLa cell lysates using anti-GFP antibody and immunoblotting with anti-v-ATPase A, -v-ATPase B or 
LAMTOR1 antibodies. A cropped blot is here displayed and the corresponding full-length blot is included in 
the supplementary information. (e) SDS-PAGE of fractions following co-immunoprecipitation of v-ATPase A, 
v-ATPase B or LAMTOR1 from lysates of HeLa cells expressing GFP or GFP-WipB and immunoblotting with 
anti-GFP antibody. A cropped blot is here displayed and the corresponding full-length blot is included in the 
supplementary information.
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To investigate whether the GFP-WipB puncta were targeted to any specific cellular compartment or whether 
GFP-WipB expression influenced the distribution or morphology of cellular organelles, GFP-WipB transfected 
cells were fixed and co-stained with markers characteristic of different subcellular compartments and orga-
nelles. GFP-WipB did not co-localise or disrupt the morphology of the Golgi apparatus (giantin), mitochondria 
(MitoTracker®) or the rough endoplasmic reticulum (calreticulin) (Fig. S4). However, GFP-WipB was strongly 
enriched around LAMP-1 positive compartments (Fig. 3b). Similarly, when transfected cells were loaded with 
LysoTracker® that specifically labels acidified compartments, LysoTracker-positive compartments also coincided 
with WipB puncta (Fig. 3c). In addition, when cells expressing GFP-WipB were loaded with TRITC-Dextran 
10,000, which accumulates in endosomal compartments, partial co-localisation with the WipB puncta was 
also evident (Fig. S3d). Indeed, GFP-WipB could be frequently and reproducibly visualised as a defined ring 
of fluorescence surrounding LAMP-1 positive, LysoTracker-positive and TRITC-Dextran loaded compart-
ments in transfected cells (Fig. 3c and S3d, zoom panels), indicative of protein recruitment. We next assessed 
the extent of colocalisation by calculating Manders coefficients to allow an unbiased evaluation of the degree of 
overlap between GFP-WipB and the various cellular markers. The resulting quantitative analysis strongly rein-
forced our qualitative observations, demonstrating statistically significant associations between WipB-GFP and 
LysoTracker, WipB-GFP and TRITC-Dextran, and most strikingly between WipB-GFP and LAMP1, but not 
between WipB-GFP and giantin (Fig. S3e). Correspondingly, the reciprocal analysis confirmed identical rela-
tionships when co-localisation was considered with respect to the individual cellular markers and GFP-WipB 
(Fig. S3e). These data reveal that the Ser/Thr phosphatase WipB is recruited to acidified LAMP1 compartments, 
characteristic of lysosomes.
To establish whether the Ser/Thr phosphatase activity influenced WipB localisation, cells were equivalently 
transfected with the catalytically dead GFP- WipBD118A derivative. As with active GFP-WipB, GFP- WipBD118A 
was stable after expression (Fig. S3a), and adopted a localisation indistinguishable from GFP-WipB (Figs 3a, S3d 
and S3f), demonstrating that Ser/Thr phosphatase activity is not a determinant of WipB localisation in eukaryotic 
cells.
To identify the region of WipB responsible for lysosomal targeting, GFP fusions of the isolated catalytic 
domain (GFP-WipB1-364) and C-terminal domain (GFP-WipB365-524) were equivalently transfected. Analysis 
of protein expression by immunoblotting of transfected cell lysates showed that each derivative was stably 
expressed as a fusion of the expected molecular weight (Fig. S3a). GFP-WipB1-364 and GFP-WipB365-524 were then 
visualised following transfection of HeLa cells using confocal microscopy (Fig. 3a). In contrast to GFP-WipB, 
GFP-WipB1-364 distributed uniformly throughout the cytoplasm, mirroring the localisation of control GFP. 
Strikingly, GFP-WipB365-524 exhibits a localization similar to GFP-WipB, demonstrating that the C-terminal 
domain is sufficient for lysosomal targeting.
WipB interacts with components of the eukaryotic LYNUS apparatus. The targeting of the 
WipB Ser/Thr phosphatase to lysosomes by the C-terminal domain, suggested that WipB might target host 
phosphoproteins within the endo-lysosomal system. To identify potential host targets of WipB, we performed 
co-immunoprecipitation experiments with anti-GFP antibodies from transfected cell lysates, followed by mass 
spectrometry analysis, using HeLa cells expressing GFP-WipB, the catalytically dead derivative GFP-WipBD118A, 
or GFP alone as a control. The proteins identified under each condition were compared and purged of those inter-
acting with GFP alone. The proteins remaining in the GFP-WipB and GFP-WipBD118A datasets were strikingly 
enriched for lysosomal proteins with 23% of the lysosomal membrane proteome represented amongst the data18. 
Amongst the common targets, we identified lysosomal proteins present within the top 50 hits that are also pre-
dicted to contain Ser/Thr phosphorylation sites according to the UNIPROT database. This identified flotillin-1, 
LAMTOR1 (p18), and two subunits of the vacuolar H+-ATPase (v-ATPase), subunits B and d1 (Table 2). Three 
of these four proteins are functionally linked, as LAMTOR1 and the two v-ATPase subunits interact as part of 
a larger macromolecular assembly termed the lysosomal nutrient sensing (LYNUS) apparatus that controls the 
mammalian target of rapamycin (mTORC1) kinase complex at the lysosomal surface19. LAMTOR1 is a phos-
phoprotein that links the Ragulator complex to the lysosomal surface, which is also involved in mTOR signalling 
and is activated via the v-ATPase20. Therefore, we focussed on these three WipB interactors.
Firstly, we verified our mass spectrometry results by immunoblotting the anti-GFP immunoprecipitation sam-
ples using antibodies specific for subunits A and B of the v-ATPase and against LAMTOR-1 (Fig. 3d and Fig. S5a). 
These data show that GFP-WipB and GFP-WipBD118A, but not GFP alone, can indeed immunoprecipitate the 
three target proteins.
Accession 
number Protein
GFP-
WipB1
GFP-
WipBD118A1
GFP-
WipB1-364
Phosphorylation 
site(s)2
O75955 Flotillin-1 + + − +
Q6IAA8 Ragulator complex protein LAMTOR1 + + − +
P21281
V-type proton 
ATPase subunit B, 
brain isoform
+ + + +
P61421 V-type proton ATPase subunit d 1 + + + +
Table 2. Lysosomal proteins present within the 50 top-scores for both the pull-downs performed with the wild-
type or D118A GFP-WipB. 1Within the 50 best scores, 2As referenced in Uniprot.
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Secondly, equivalent immunoprecipitations with N-terminal GFP-WipB1-364 and C-terminal GFP-WipB365-524 
were performed (Fig. 3d and Fig. S5a). While GFP-WipB365-524 interacts with the two v-ATPase subunits and 
LAMTOR1, GFP-WipB1-364 only binds the v-ATPase subunits. This reveals that while both domains of WipB can 
engage with the v-ATPase subunits, only the C-terminal domain can interact with LAMTOR1.
Finally, we performed reverse co-immunoprecipitation using antibodies against the v-ATPase A and B subu-
nits and LAMTOR1 (Fig. 3e and Fig. S5b). Cells were transfected with either GFP alone or GFP-WipB and lysates 
incubated in the presence of beads coupled to antibodies against the v-ATPase A or B subunits, or LAMTOR1. 
Immunoprecipitated proteins were then analysed by SDS-PAGE and Western blotting using anti-GFP antibody. 
As shown in Fig. 3e, all three proteins were able to pull-down GFP-WipB, but not GFP alone.
Altogether, these results show that the WipB Ser/Thr phosphatase targets key components of the host LYNUS 
complex on the lysosome, when expressed in mammalian cells.
Discussion
In this study, we determined the structure and characterized the catalytic domain of the Legionella pneumophila 
effector WipB. We showed that this domain belongs to the PPP family of eukaryotic phosphatases and has a Ser/
Thr phosphatase activity in vitro21.
Ser/Thr phosphatases regulate a wide number of processes in eukaryotic cells, including targeting signalling 
cascade components to membrane receptors14. Their substrate(s) specificity often resides within their regulatory 
domains/subunits. Similarly, we showed that WipB has a specific subcellular localisation in HeLa cells controlled 
by its C-terminal domain, which targets it to lysosomes.
We demonstrated that WipB can interact with subunits of the v-ATPase and LAMTOR1 when expressed 
in cultured cells. The v-ATPase is a transmembrane complex that controls the acidification of cellular orga-
nelles, comprised of 17 subunits22, which harbour several phosphorylation sites that regulate pump function23. 
Legionella may modulate the function of the v-ATPase since part of the LCV membrane is derived from the 
lysosomal compartment24, 25, yet the lumen remains at neutral pH26. Indeed, the Legionella effector SidK binds 
the v-ATPase regulatory subunit VatA, resulting in the inhibition of the complex and organelle acidification26. As 
with wipB mutants, a sidK mutant did not exhibit defects in intracellular replication26. Consequently, it is possible 
that redundant functions of SidK and WipB converge to repress the activity of the host v-ATPase through direct 
binding, promoting bacterial growth.
Recently, mTOR-driven metabolic reprogramming was found to be important for intracellular replica-
tion by Legionella27. An unknown T4S effector/s was proposed to activate mTOR to promote LCV expansion, 
a process that required a functional Dot/Icm secretion system and the IcmS chaperone, in addition to host 
phosphatidylinositol-3-kinase. Lysosomes play an important role in coordinating nutrient sensing and signal-
ling pathways involved in cell metabolism and growth. LAMTOR1 is a key phosphoprotein of this system20, 
directing the nucleation of the multi-component LYNUS apparatus including mTOR and v-ATPase on the lys-
osomal surface19, although its mode of regulation are not yet clearly understood. Although further investigation 
is required, it is tempting to speculate that WipB is a T4S effector involved in the metabolic reprogramming of 
Legionella-infected cells.
Using transposon site hybridization (TraSH), several “functional groups” of effectors were proposed to con-
comitantly act on cellular pathways: while individual effector deletion has no effect, their combined deletion 
altered L. pneumophila growth in host cells11. While single deletion of wipB and lidA are phenotypically silent, 
a wipB/lidA double mutant exhibited defects in the stability of the LCV. During infection, LidA promotes the 
recruitment of ER-derived vesicles to the LCV through its binding to the AMPylated form of the Rab1 GTPase28. 
In this manner, LidA contributes to replication-niche formation, essential for L. pneumophila to gather the 
resources it needs for cell division. On the other hand, escaping the host defence mechanisms by repressing the 
lysosomal pathway, a process WipB could be involved in, appears crucial to bacterial survival. Thus, impairing 
both LidA and WipB function would alter two main complementary virulence strategies, eventually leading to 
intracellular growth defects.
A recent genetic study conducted on the genomes of 41 Legionella species remarkably showed that effector 
repertories share some conserved domains within and between species29. Those domains, catalytic, binding or 
uncharacterized domains, are shuffled to generate effector pools, which consist of nearly 6000 effectors in the 
whole sequenced genus. Using the L. pneumophila effectors, the authors define 608 orthologue groups of proteins 
sharing one or several conserved domains, representing 80% of the 6000 putative proteins. One orthologue group 
is based on the WipB sequence (group number LOG_00109), which according to their findings, could have ort-
hologues in 32 out of the 41 sequenced Legionella species. In addition, a search of homologues to the WipB cata-
lytic domain using BLAST30 also identifies hypothetical proteins effectors in Coxiella and Fluoribacter species that 
could then share the same enzymatic activity. Thus our findings on L. pneumophila WipB might have implications 
for understanding a whole family of effectors from the entire Legionella genus.
L. pneumophila secretes a wide range of protein effectors during the infection that leads to Legionnaire’s dis-
ease. Assigning the functions of these effectors is often complex given the high redundancy they exhibit. Here we 
demonstrate how combining structural biology and cellular biology is a powerful alternative route to identifying 
the role and targets of Legionella effectors.
Methods
Cloning. The WipB DNA (AAU28775) encoding the wild type protein (Q5ZS02_LEGPH, lpg2718) was 
cloned in a modified pETM14 vector (EMBL) or in empty pEGFP-C2 and -N2 vectors using a PCR-based in-fu-
sion HD cloning system (Clontech Laboratories). For the pETM14-derived constructs, the expression cassette 
contained an N-terminal deca-histidine tag followed by a 3 C protease cleavage site. Site directed mutagenesis was 
performed using standard molecular biology protocols.
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Expression and purification of WipB25-344 and WipB1-364. All recombinant proteins were 
over-expressed in C43(DE3) bacterial strains. The cells were harvested by centrifugation (6000 g, 15 min) and 
resuspended in a lysis buffer containing 25 mM Tris-HCl pH 7.5, 0.3 M NaCl, 5 mM β-mercaptoethanol (βME), 
10 mM imidazole, 5% glycerol, a tablet of protease inhibitors (Complete, EDTA-free by Roche) and 0.25 mg/ml 
lysozyme. Cells were lysed in an EmulsiFlex-C3 homogeniser (Avestin) and the crude extract was centrifuged at 
50,000 g for 45 min. The supernatant was loaded onto a 5 ml HisTrap column (GE Healthcare) equilibrated with 
the lysis buffer, connected on an AKTA purifier (GE Healthcare). Washing steps were performed with extended 
volumes of lysis buffer though the column as well high salt buffer (25 mM Tris-HCl pH 7.5, 1 M NaCl, 5 mM 
βME, 10 mM imidazole, 5% glycerol). The protein was eluted using an imidazole gradient (Elution buffer: 25 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 5 mM βME, 0.6 M imidazole, 5% glycerol). The eluted protein was dialyzed 
overnight against buffer A (25 mM Tris-HCl pH 7.5, 5% glycerol) in presence of 3C-protease fused to GST to a 
molar ratio protein/protease of 50:1. The cleaved protein was collected in the flowthrough of two 1 ml HisTrap 
and GST-Trap columns (GE Healthcare) connected in sequence to remove uncleaved proteins and the protease. 
It was then loaded on a resource Q column (GE healthcare) and eluted with a gradient of NaCl at a concentration 
of about 0.1 M NaCl. The eluted protein was further concentrated and loaded to a superdex200 16/60 column (GE 
healthcare) equilibrated in 25 mM Tris-HCl pH 7.5, 0.15 M NaCl, and 5% glycerol.
Phosphatase activity assay. Assays were conducted on purified protein after His-tag removal using the 
Tyrosine and Ser/Thr Phosphatase Assay Systems kits (Promega). Briefly, the protein was diluted in its purifica-
tion buffer containing 1 mM of MnCl2 and incubated at either 21 °C or 37 °C with the provided peptide before 
stopping the reaction with a buffer containing molybdate and malachite green to measure free phosphate at 
600 nm in a 96-well microplate. One phosphothreonine-containing peptide (sequence RRA(pT)VA) and two 
phosphotyrosine-containing peptides (END(pY)INASL and DADE(pY)LIPQQG) were provided in the kits and 
were used as per manufacturer’s instructions.
Crystallization, data collection and processing. Initial crystallization screens were performed using 
the sitting-drop vapor-diffusion technique, by mixing equal volumes (0.2 μl) of protein solution (13 mg/ml) at 
16 °C. Crystals in the shape of thin needles appeared after 3-4 days reaching a maximum length of 0.1-0.2 mm 
against a reservoir solution containing 0.23 M ammonium citrate dibasic and 22% PEG3000. Before data col-
lection, harvested crystals were immersed in a solution containing the precipitant mixture and 10% MDP and 
cryo-cooled in liquid nitrogen. All data sets were collected at 100 K. Crystals of the WipB25-344 were collected at 
the PetraIII P13 beam-line (EMBL-Hamburg/DESY P13, Germany). The data set was indexed, processed and 
scaled using the XDS package31, (Table 1).
Structure determination and refinement. The WipB25-344 crystals belonged to the P 21 space group with 
a solvent content of 43.12% corresponding to two molecules per asymmetric unit (AU). The structure was deter-
mined by molecular replacement using MOLREP32 and the WipA structure (PDB Code 5N72) containing only the 
α-helices and β-strands of the phosphatase domain as search model. The coordinates were further improved by 
maximum-likelihood and TLS refinement using the PHENIX suite33 and manual improvements of the model using 
COOT34. The final model converged to a final Rwork/Rfree of 0.187/0.217 at a resolution of 1.70 Å. The WipB25-344 
model covers the WipB amino-acid sequence 24-331 (chain A) and 25–344 (chain B) and contains in addition 
484 water molecules.
Antibodies and cellular biology reagents. CHIP grade rabbit anti-GFP (Invitrogen) was used for 
co-immunoprecipitation and mouse anti-GFP (clontech) for Western-blotting. Rabbit anti-vATPase A (Abcam), 
anti-vATPase B (Abcam) or anti-LAMTOR1 (Sigma) were used for co-immunoprecipitation and Western blot-
ting. Anti-Sec. 61b (Millipore) was used as a loading control in Western-blotting. HRP-coupled anti-mouse 
and anti-rabbit (Invitrogen) and TrueBlot anti-rabbit (Rockland) were used for Western-blotting and detected 
using ECL kit (GE Healthcare). For cell labelling, we used anti-LAMP1 (rabbit, NEB), anti-Giantin (rabbit, 
Covance), anti-LaminA/C (mouse, Santa Cruz), and MitoTracker, LysoTracker Red, Dextran TRITC 10,000 and 
Transferrin647 were purchased from Thermofisher.
Cell culture, transfection, labelling and microscopy. Hela cells were routinely cultured, transfected 
and immunolabeled as previously described35. For in vivo labeling, cells were incubated at 37 °C for 15 min-
utes with Dextran TITRC 10,000 at 1 mg/ml, MitoTracker at 250 nM, Transferrin-Alexa647 at 0.025 mg/ml or 
LysoTracker Red at 50 nM in DMEM then washed in HBSS. Transferrin-labeled cells were stripped in stripping 
buffer (150 mM NaCl, 100 mM Glycine, 5 mM KCl, 1 mM CaCl2, pH4.5).
Cells were imaged using a confocal microscope (TCS Sp5 AOBS; Leica) with an oil-immersion objective 
(63 × , 1.4 NA; Leica) as previously described35. Images were analyzed using Fiji36.
Mass spectrometry analysis. HeLa cells were sonicated 24 h after transfection in PBS containing protease 
inhibitors. Lysates were incubated for 30 min at 30 °C with beads coupled to anti-GFP antibodies equilibrated 
in PBS Tween 0.02%(v/v). After washing, beads were processed in mass spectrometry as described previously35.
Co-immunoprecipitation. Dynabeads protein G (Thermofisher) were incubated with anti-GFP, 
anti-vATPase A, anti-vATPase B or anti-LAMTOR1 antibodies in a buffer PBS Tween 0.02% (v/v) 10% BSA 
(w/v) for 10 min. Cell lysates were incubated with the washed beads for 1 h in the presence of 5% BSA to reduce 
non-specific interactions. After washing, proteins were eluted with 75 mM Tris HCl pH 7.4, 0.5 M EDTA, 0.05% 
SDS and analyzed by western blotting.
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